AbbVie Inc (NYSE ABBV), the speciality pharma firm spun off from Abbott Laboratories (NYSE ABT) almost a year ago, and Google Inc (NASDAQ GOOG) new Calico division will spend up to $1.5 billion to research cures to age-related diseases such as cancer and neurodegenerative disorders. Google’s Calico and AbbVie forms a $1,5 billion aging-related disease…
With Facebook Inc (NASDAQ FB)’s stock opening at $77 a share in trading today, it pushed its market capitalization over $200 billion joining other tech giants in this rarefied air. That is an effective doubling of the company’s market cap from when it went public in May of 2012 and nearly four times its low…
Apple Inc (NASDAQ AAPL) is expected to unveil the iPhone 6 and possibly other gadgets like the rumored iWatch at its planned event next week. The company’s stock has been climbing ahead of that unveiling—just as it has historically—but apparently investors are worrying because of what the company’s top competitor has just shown off. Shares…
After a post-earnings slide, Microsoft Corporation (NASDAQ MSFT) has seen its stock price recover and gain slightly, but some critics remain unconvinced that the tech giant can justify price multiples that would have been considered cheap ten years ago. Indigo Equity Research argues that Microsoft is still too dependent on the PC market and has…
Two top-ranked US universities, New York University and Duke University, are offering courses on cryptocurrencies for the first time. Professor Geoffrey Miller taught the first class of NYU’s new course, The Law and Business of Bitcoin and Other Cryptocurrencies, yesterday. 35 students attended the session – the first in a series of 14 – which…
Amgen Inc (AMGN) received encouraging news from the FDA as the regulatory body granted priority review status to the New Drug Application (NDA) for its pipeline candidate, ivabradine. Amgen is looking to get ivabradine approved for the treatment of chronic heart failure. Te FDA grants priority review status to candidates which have the potential to…
